ProBioGen Introduces Pathway Modulator Technology for Therapeutic Protein Production

The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells.

ProBioGen announced the implementation of its new “Pathway Modulator Technology“, a permanent modification of animal cell lines for substantially improved protein yields.

The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes’ concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs.

For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.